HeartBeam Completes Patient Enrollment Ahead of Schedule in ALIGN-ACS Pilot Study for Heart Attack Detection HeartBeam, Inc., a medical technology company focused on advancing cardiovascular diagnostics through innovative electrocardiogram (ECG)…
Colossal Foundation and University of Tasmania Launch Multi-Pronged Initiative to Combat Deadly Tasmanian Devil Facial Tumour Disease The Colossal Foundation, the nonprofit conservation organization established by Colossal Biosciences, has announced…
FNIH and Leading Advocates Launch Music as Medicine Neuroscience Initiative The Foundation for the National Institutes of Health (FNIH) has announced the launch of the Music as Medicine Neuroscience Research…
CorVista Health Receives New AMA Category III CPT Code for AI-Powered Cardiovascular Diagnostic Technology CorVista Health has announced that the American Medical Association (AMA) has approved a new Category III…
Croma-Pharma Secures FDA Approval for Obagi saypha® ChIQ™ to Expand Facial Aesthetic Treatment Options in the U.S. Croma-Pharma has reached another significant milestone in its global growth strategy with the…
Hengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment Hengrui Pharma and Novaliq GmbH have announced that China’s National Medical Products Administration (NMPA) has approved Heng Yi® (0.1%…
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Candidate Fizurex™ Altasciences has announced the successful completion of a pivotal toxicology study for Steel Therapeutics Inc.’s lead investigational therapy, Fizurex™,…
Caidya and Simbec-Orion Unite to Create Global Specialty CRO for End-to-End Drug Development Caidya has announced a strategic combination with Simbec-Orion, marking a significant milestone in the clinical research industry…
BRUKINSA Phase 3 Trial Shows Chemotherapy-Free Promise for Frontline Mantle Cell Lymphoma BeOne Medicines Ltd. has announced positive topline findings from its pivotal Phase 3 MANGROVE clinical trial, marking a…
Novocure Secures CE Mark for Optune Pax in Locally Advanced Pancreatic Cancer Novocure has achieved a significant regulatory milestone after receiving the CE (Conformité Européenne) Mark for Optune Pax®, authorizing…
Kriya Therapeutics Selected for FDA PreCheck Pilot Program to Advance U.S. Gene Therapy Manufacturing Kriya Therapeutics, Inc., a biotechnology company focused on developing durable gene therapies for chronic diseases, has…
Samsung Bioepis Reports Positive Phase 1 and Phase 3 Results for SB27, Its Proposed Pembrolizumab Biosimilar Samsung Bioepis Co., Ltd. has announced encouraging topline results from its Phase 1 and…
